Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew (SNN) reported Q2 2026 underlying revenue growth of 1.6%, with softness in U.S. Orthopaedics and Advanced Wound Bioactives. First-half trading profit was $566 million, helped by $128 million efficiency savings. It revised 2026 revenue outlook to about 4% and guided full-year free cash flow around $800 million.
How this was made
The 30-second read
Why it matters
Management lowered the full-year underlying revenue growth outlook to around 4% from prior expectations, citing U.S. knees and SANTYL performance, while maintaining trading profit strength and providing free cash flow guidance of about $800M.
Market read
The most actionable update is the revised 2026 revenue outlook alongside maintained profit and cash flow guidance, with quantified headwinds (China VBP, skin substitutes) and quantified growth (Sports Medicine, REGENETEN).
What to watch
The call attributes headwinds to reimbursement and distributor timing (SANTYL, skin substitutes) and China inventory restrictions; traders may need to monitor whether these normalize faster than management’s upper-end impact range.
Background
This is Smith & Nephew’s Q2 2026 earnings call transcript covering first-half performance, segment drivers, and revised full-year 2026 outlook.
Ticker impact
Smith & Nephew guided 2026 underlying revenue growth to around 4% and reiterated free cash flow of about $800M, citing U.S. knees and SANTYL headwinds.
Near-term trading likely hinges on whether investors view the lowered revenue outlook as offset by margin resilience and cash flow guidance.
The article provides specific guidance changes (revenue outlook lowered) plus quantified profit/cash flow and segment drivers (Sports Medicine growth, wound bioactives decline, China VBP and skin substitute headwinds).
Market effects
Signals ongoing reimbursement and inventory timing pressure in wound care, while orthopedics execution remains the key swing factor for medtech earnings durability.
Highlights U.S. Orthopaedics weakness and U.S. skin substitute reimbursement friction as primary regional drags.
China VBP and global robotic platform adoption (CORI deployments) point to uneven demand and policy-driven procurement effects across regions.
Counterpoint
Investors may discount the maintained cash flow guidance if the revenue reset implies weaker demand that could later pressure margins and working capital.
Key entities
- companySmith & Nephew
Provided Q2 and first-half results, revised 2026 revenue outlook, and segment-level drivers including Sports Medicine growth and Advanced Wound Bioactives headwinds.
- executiveDeepak Nath
CEO who discussed orthopaedics portfolio gaps, LANDMARK launch timing, and FDA approval for TESSA.
- executiveJohn Rogers
CFO who quantified margin, cash flow, and headwinds from reimbursement changes and China VBP inventory restrictions.
